Université deSherbrooke
Welcome,         Profile    Billing    Logout  
 10 Trials 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Turcotte, Eric
NCT04842071: 18F-sodium Fluoride (NaF) PET to Replace Bone Scintigraphy: Safety and Efficacy Assessment

Recruiting
3
2500
Canada
18F-sodium fluoride, 18F-NaF
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Université de Sherbrooke
Bone Cancer, Articular Disease, Infectious Disease
12/25
12/25
NCT04824014: 4FMFES-PET Imaging of ER+ Advanced Breast Cancers

Recruiting
2
150
Canada
4FMFES-PET, 4,16α-[16α-18F]difluoro-11β-methoxyestradiol PET
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Canadian Cancer Society (CCS), Université de Sherbrooke
ER+ Breast Cancer
12/25
12/25
NCT05974579: Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated with Amyotrophic Lateral Sclerosis

Active, not recruiting
1
12
Canada
89Zr-DFO-AP-101
Université de Sherbrooke, Eli Lilly and Company, Chorus Wellness Inc.
Amyotrophic Lateral Sclerosis
12/24
03/25
NCT06147037: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours

Recruiting
1
110
Canada, US
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Fusion Pharmaceuticals Inc., AstraZeneca
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/26
12/27
GB8, NCT05092945: Brown Adipose Tissue Metabolism in Type 2 Diabetes

Recruiting
N/A
40
Canada
Cold exposure, Oral Nicotinic acid, Niacin 500 (Jamp Pharma) NPN 00557412
Université de Sherbrooke
Type 2 Diabetes
09/25
12/25
Turcotte, Éric E
NCT04842071: 18F-sodium Fluoride (NaF) PET to Replace Bone Scintigraphy: Safety and Efficacy Assessment

Recruiting
3
2500
Canada
18F-sodium fluoride, 18F-NaF
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Université de Sherbrooke
Bone Cancer, Articular Disease, Infectious Disease
12/25
12/25
NCT04847505: 68Ga-DOTA-TATE PET/CT Imaging in NETs

Recruiting
3
5000
Canada
68Ga-DOTA-TATE, Netspot
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Université de Sherbrooke, Jewish General Hospital
Neuroendocrine Tumors
12/25
12/25
NCT04823065: 4FMFES-PET Imaging of Endometrial and Ovarian Cancers

Completed
1/2
53
Canada
Loperamide Pill, Imodium, hyoscine-n-butylbromide, Buscopan
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Université de Sherbrooke
Endometrial Cancer, Ovarian Cancer
08/23
04/24
NCT06732336: HER2-PET Imaging in HER2-low Breast Cancers

Recruiting
1/2
40
Canada
89Zr-trastuzumab
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Université de Sherbrooke
Breast Cancer Metastatic
03/26
03/26
NCT06147037: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours

Recruiting
1
110
Canada, US
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Fusion Pharmaceuticals Inc., AstraZeneca
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/26
12/27
TIMED, NCT05123963: Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors

Recruiting
N/A
48
Canada
High-intensity interval training
Université de Sherbrooke, University of Calgary, University of Waterloo, Laval University, Wageningen University, Maastricht University Medical Center, Leiden University Medical Center, McMaster University, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Prediabetic State
12/24
04/25
NCT05228106: 68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study

Recruiting
N/A
1000
Canada
[68Ga]-PSMA-617, PSMA-PET
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Solid Cancers
01/27
01/27
Pavic, Michel
NRG-BR003, NCT02488967: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Active, not recruiting
3
782
Canada, US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
10/26
10/26
NCT04824014: 4FMFES-PET Imaging of ER+ Advanced Breast Cancers

Recruiting
2
150
Canada
4FMFES-PET, 4,16α-[16α-18F]difluoro-11β-methoxyestradiol PET
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Canadian Cancer Society (CCS), Université de Sherbrooke
ER+ Breast Cancer
12/25
12/25
CCTG PR21, NCT04663997: 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Active, not recruiting
2
200
Canada
177Lu-PSMA-617, Docetaxel
Canadian Cancer Trials Group, Prostate Cancer Canada, Novartis Pharmaceuticals
Prostate Cancer
06/25
12/25
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Urothelial Carcinoma
11/26
05/28
COBRA, NCT05220098: First-in-Human Study of TAK-280 in Participants With Solid Tumors

Recruiting
1/2
182
Europe, Canada, US, RoW
TAK-280
Takeda, Takeda Development Center Americas, Inc.
Unresectable Locally Advanced or Metastatic Cancer
02/25
07/26
iinnovate-3, NCT05590377 / 2022-002169-14: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Completed
1/2
15
Europe, Canada, US, RoW
Modakafusp Alfa, TAK-573, Daratumumab
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
05/24
05/24
NCT06147037: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours

Recruiting
1
110
Canada, US
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Fusion Pharmaceuticals Inc., AstraZeneca
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/26
12/27
NCT06551142: A Study of GSK5764227 in Participants With. Advanced Solid Tumors

Recruiting
1
240
Canada, Japan, US, RoW
GSK5764227, Cisplatin, Carboplatin, Atezolizumab, Pembrolizumab, Durvalumab, Fluorouracil, Folinic acid, Cetuximab, Bevacizumab
GlaxoSmithKline
Neoplasms
07/26
03/27
Guérin, Brigitte
NCT04824014: 4FMFES-PET Imaging of ER+ Advanced Breast Cancers

Recruiting
2
150
Canada
4FMFES-PET, 4,16α-[16α-18F]difluoro-11β-methoxyestradiol PET
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Canadian Cancer Society (CCS), Université de Sherbrooke
ER+ Breast Cancer
12/25
12/25
NCT05974579: Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated with Amyotrophic Lateral Sclerosis

Active, not recruiting
1
12
Canada
89Zr-DFO-AP-101
Université de Sherbrooke, Eli Lilly and Company, Chorus Wellness Inc.
Amyotrophic Lateral Sclerosis
12/24
03/25
3TMPO, NCT04000776: (Triple-Tracer Strategy Against Metastatic Prostate Cancer

Completed
N/A
100
Canada
FDG Positron emission tomography (PET) scan, PSMA Positron emission tomography (PET) scan, OCTREOTATE Positron emission tomography (PET) scan, Optional Bone or soft-tissue biopsies
Université de Sherbrooke, Fonds de la Recherche en Santé du Québec, Oncopole, Canadian Cancer Society (CCS), Merck Canada Inc.
Metastatic Castration-resistant Prostate Cancer
03/23
06/23
Turgeon, Guy-Anne
NCT04824014: 4FMFES-PET Imaging of ER+ Advanced Breast Cancers

Recruiting
2
150
Canada
4FMFES-PET, 4,16α-[16α-18F]difluoro-11β-methoxyestradiol PET
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Canadian Cancer Society (CCS), Université de Sherbrooke
ER+ Breast Cancer
12/25
12/25
Rousseau, Étienne
NCT04824014: 4FMFES-PET Imaging of ER+ Advanced Breast Cancers

Recruiting
2
150
Canada
4FMFES-PET, 4,16α-[16α-18F]difluoro-11β-methoxyestradiol PET
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Canadian Cancer Society (CCS), Université de Sherbrooke
ER+ Breast Cancer
12/25
12/25

Download Options